CSI Market
Sign In | Register

Ascendis Pharma A (ASND) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ASND Annual Cash Flow →
A period-by-period view of cash flow from Ascendis Pharma A to Dec 31 2024 helps clarify how Dec 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		0 0 0 (Dec 31 2024)
Operating Activities
Income-255.40
Depreciation & amortization19.27
Amortization of Other Assets0.55
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss PropertyPlant And5.92
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Income Tax Expense Continuing Operations-
Adjustments For Non Cash Consideration Regarding Revenue-
Share Of Profit Loss Of Associates Accounted For Using Equity Method-
Adjustments For Sharebased Payments-
Adjustment For Decrease Increase In Trade Receivables Other Receivables And Other Short Term Deposits-
Adjustments For Increase Decrease In Prepayments-
Adjustments For Increase Decrease In Deferred Income-
Adjustments For Increase Decrease In Trade And Other Payables-
Finance Income Received Classified As Operating Activities-
Finance Costs Paid Classified As Operating Activities-
Income Taxes Paid Refund Classified As Operating Activities-
Income taxes0.00
Proceeds From Disposal Or Maturity Of Availableforsale Financial Assets0.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities271.30
Discontinued operations0.00
Net Cash flow from Operating Activities136.76
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds From Sales Or Maturity Of Financial Instruments Classified As Investing Activities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Purchase Of Intangible Assets And Property Plant And Equipment-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Purchase Of InterestsIn Associates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-9.50
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net40.69
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities40.69
Effect of exchange rate on cash flow91.55
Discontinued operations0.00
Free Cash Flow136.76
Total Cash Flow626.69
4 historic quarters locked

Sign in to unlock the full Ascendis Pharma A cash flow history.

Sign In Create Free Account

About Ascendis Pharma A s Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: February 11, 2026
  • Source: asnd-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-046590

Figures are derived from filed reports and may be restated. Historical data is subject to revision.